Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO Tracks Decline In ESA Use Following Regulatory Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.


Related Content

Epogen Use Re-Calculation Drives 9.4% Medicare ESRD Bundled Payment Cut In 2014
Patient-Reported Outcomes Are Key To Understanding Success of Bundled Payments – NPC’s Dubois
Medicare ESRD Payment Should Account For Epogen Price Increase, Dialysis Centers Say
Bill To Overturn Delay In Bundling Oral-Only Drugs For ESRD Introduced
Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix
ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts